Valneva SE
VALN- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001836564
No open-market purchases or sales by Valneva SE insiders were filed in the last 90 days; 20 institutions reported holding it in 13F filings for Q2 2026, worth $19.8M in total; no superinvestor holds it.
Q3 2023 vs. Q2 2023
How the institutions holding Valneva SE changed between Q2 2023 and Q3 2023.
All holders in Q3 2023All holders in Q2 2023
| Measure | Q2 2023 | Q3 2023 | Change |
|---|---|---|---|
| Holders | 11 | 10 | −1 |
| Shares | 378.3K | 397.4K | +19.1K (+5.1%) |
| Value | $5.55M | $4.69M | −$866.0K (−15.6%) |
New holders (3)
Institutions that held Valneva SE at the end of Q3 2023 but not at the end of Q2 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| AlphaCentric Advisors LLC | 20,590 | $243.0K | 0.14% |
| JPMorgan Chase & Co | 39 | $460 | 0.00% |
| Qube Research & Technologies Ltd | 22 | $260 | 0.00% |
Sold out (4)
Institutions that held Valneva SE at the end of Q2 2023 and filed for Q3 2023 without it.
| Institution | Shares, Q2 2023 | Value, Q2 2023 |
|---|---|---|
| Ridgewood Investments LLC | 550 | $8.11K |
| Barclays PLC | 170 | $2.51K |
| UBS Group AG | 2 | $30 |
| Ronald Blue Trust, Inc. | 6 | $0 |